Table 2.
Real-time RT-PCR Analysis Data in the Hippocampal Dentate Gyrus on PND 21 and PND 77
| 0 ppm AlCl3 (Control) |
1800 ppm AlCl3 |
|||
|---|---|---|---|---|
| Relative Transcript Level Normalized to |
Relative Transcript Level Normalized to |
|||
| Gapdh | Hprt | Gapdh | Hprt | |
| No. of animals examineda | 6 | 6 | 6 | 6 |
| PND 21 | ||||
| Synaptic plasticity | ||||
| Arc | 1.02 ± 0.23 | 1.04 ± 0.32 | 1.63 ± 0.87 | 1.83 ± 0.80* |
| Ptgs2 | 1.02 ± 0.24 | 1.01 ± 0.13 | 0.78 ± 0.15 | 0.89 ± 0.10 |
| Fos | 1.02 ± 0.21 | 1.02 ± 0.24 | 0.98 ± 0.31 | 1.14 ± 0.38 |
| Stem cell regulation | ||||
| Kitl | 1.02 ± 0.25 | 1.04 ± 0.32 | 0.78 ± 0.19 | 1.02 ± 0.37 |
| Notch1 | 1.03 ± 0.28 | 1.07 ± 0.42 | 0.89 ± 0.29 | 1.14 ± 0.43 |
| Cell proliferation | ||||
| Pcna | 1.01 ± 0.15 | 1.00 ± 0.06 | 0.71 ± 0.15** | 0.81 ± 0.12** |
| Neurotrophic action | ||||
| Ntrk2 | 1.03 ± 0.29 | 1.09 ± 0.52 | 0.98 ± 0.19 | 1.29 ± 0.45 |
| Bdnf | 1.07 ± 0.42 | 1.08 ± 0.48 | 1.21 ± 0.28 | 1.60 ± 0.60 |
| Cholinergic receptors | ||||
| Chrna7 | 1.03 ± 0.30 | 1.04 ± 0.34 | 1.13 ± 0.39 | 1.29 ± 0.35 |
| Chrna4 | 1.01 ± 0.17 | 1.07 ± 0.43 | 0.66 ± 0.25* | 0.82 ± 0.28 |
| Chrnb2 | 1.02 ± 0.20 | 1.02 ± 0.20 | 0.82 ± 0.11 | 0.95 ± 0.13 |
| Glutamate transporters/receptors | ||||
| Slc17a6 | 1.05 ± 0.41 | 1.05 ± 0.37 | 0.47 ± 0.22* | 0.58 ± 0.21* |
| Slc17a7 | 1.12 ± 0.63 | 1.15 ± 0.76 | 1.94 ± 0.97 | 2.19 ± 0.89 |
| Gria1 | 1.09 ± 0.53 | 1.10 ± 0.48 | 1.12 ± 0.28 | 1.44 ± 0.47 |
| Gria2 | 1.10 ± 0.50 | 1.09 ± 0.53 | 1.52 ± 0.59 | 2.00 ± 0.93 |
| Gria3 | 1.03 ± 0.25 | 1.02 ± 0.22 | 1.37 ± 0.44 | 1.56 ± 0.39* |
| Grin2a | 1.07 ± 0.41 | 1.07 ± 0.45 | 1.77 ± 0.69 | 2.36 ± 1.13* |
| Grin2d | 1.02 ± 0.24 | 1.11 ± 0.52 | 0.55 ± 0.14** | 0.70 ± 0.15 |
| Apoptosis | ||||
| Bax | 1.01 ± 0.18 | 1.01 ± 0.11 | 0.78 ± 0.13* | 0.89 ± 0.09 |
| Bcl2 | 1.02 ± 0.20 | 1.00 ± 0.08 | 1.06 ± 0.32 | 1.22 ± 0.30 |
| Casp2 | 1.01 ± 0.17 | 1.02 ± 0.22 | 1.02 ± 0.23 | 1.16 ± 0.17 |
| Casp3 | 1.04 ± 0.28 | 1.04 ± 0.31 | 0.97 ± 0.12 | 1.27 ± 0.36 |
| Casp9 | 1.02 ± 0.18 | 1.01 ± 0.16 | 0.95 ± 0.16 | 1.09 ± 0.14 |
| Casp12 | 1.02 ± 0.20 | 1.02 ± 0.21 | 1.21 ± 0.28 | 1.38 ± 0.22* |
| PND 77 | ||||
| Synaptic plasticity | ||||
| Arc | 1.02 ± 0.21 | 1.01 ± 0.18 | 0.36 ± 0.14** | 0.45 ± 0.15** |
| Ptgs2 | 1.06 ± 0.44 | 1.01 ± 0.18 | 0.79 ± 0.38 | 0.96 ± 0.25 |
| Fos | 1.01 ± 0.12 | 1.02 ± 0.18 | 0.79 ± 0.31 | 0.98 ± 0.18 |
| Stem cell regulation | ||||
| Kitl | 1.14 ± 0.54 | 1.33 ± 0.55 | 1.49 ± 0.92 | 1.74 ± 0.80 |
| Notch1 | 1.02 ± 0.24 | 1.01 ± 0.35 | 0.91 ± 0.35 | 1.14 ± 0.22 |
| Cell proliferation | ||||
| Pcna | 1.02 ± 0.20 | 1.01 ± 0.16 | 0.72 ± 0.22* | 0.92 ± 0.15 |
| Neurotrophic action | ||||
| Ntrk2 | 1.02 ± 0.26 | 1.00 ± 0.09 | 0.86 ± 0.34 | 1.07 ± 0.17 |
| Bdnf | 1.05 ± 0.39 | 1.04 ± 0.29 | 0.92 ± 0.26 | 1.17 ± 0.10 |
| Cholinergic transporters/receptors | ||||
| Chrna7 | 1.07 ± 0.48 | 1.04 ± 0.32 | 0.89 ± 0.27 | 1.13 ± 0.17 |
| Chrna4 | 1.13 ± 0.60 | 1.13 ± 0.58 | 1.45 ± 0.71 | 1.75 ± 0.45 |
| Chrnb2 | 1.04 ± 0.30 | 1.03 ± 0.30 | 1.10 ± 0.49 | 1.34 ± 0.28 |
| Glutamate receptors | ||||
| Slc17a6 | 1.26 ± 0.82 | 1.26 ± 0.87 | 2.37 ± 1.35 | 2.82 ± 0.98* |
| Slc17a7 | 1.11 ± 0.62 | 1.06 ± 0.39 | 0.79 ± 0.16 | 1.03 ± 0.10 |
| Gria1 | 1.07 ± 0.47 | 1.04 ± 0.30 | 1.02 ± 0.28 | 1.31 ± 0.15 |
| Gria2 | 1.04 ± 0.33 | 1.03 ± 0.26 | 0.81 ± 0.19 | 1.05 ± 0.14 |
| Gria3 | 1.06 ± 0.44 | 1.01 ± 0.18 | 0.86 ± 0.31 | 1.11 ± 0.14 |
| Grin2a | 1.08 ± 0.52 | 1.05 ± 0.34 | 1.04 ± 0.29 | 1.33 ± 0.21 |
| Grin2d | 1.10 ± 0.52 | 1.07 ± 0.44 | 1.60 ± 0.97 | 1.91 ± 0.71* |
| Apoptosis | ||||
| Bax | 1.02 ± 0.25 | 1.00 ± 0.08 | 0.72 ± 0.15* | 0.93 ± 0.08 |
| Bcl2 | 1.05 ± 0.31 | 1.04 ± 0.29 | 0.82 ± 0.45 | 0.99 ± 0.35 |
| Casp2 | 1.02 ± 0.25 | 1.01 ± 0.19 | 1.12 ± 0.48 | 1.41 ± 0.35* |
| Casp3 | 1.02 ± 0.24 | 1.01 ± 0.17 | 0.89 ± 0.36 | 1.11 ± 0.22 |
| Casp9 | 1.04 ± 0.37 | 1.01 ± 0.16 | 1.02 ± 0.45 | 1.27 ± 0.27 |
| Casp12 | 1.09 ± 0.52 | 1.03 ± 0.27 | 0.94 ± 0.36 | 1.22 ± 0.38 |
Abbreviations: Arc, activity-regulated cytoskeletal-associated protein; Bax, BCL2-associated X protein; Bcl2, B-cell leukemia/lymphoma 2; Bdnf, brain derived neurotrophic factor; Casp2, caspase 2; Casp3, caspase 3; Casp9, caspase 9; Casp12, caspase 12; Chrna4, cholinergic receptor nicotinic alpha polypeptide 4; Chrna7, cholinergic receptor nicotinic alpha polypeptide 7; Chrnb2, cholinergic receptor nicotinic beta polypeptide 2; Fos, FBJ osteosarcoma oncogene; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Gria1, glutamate receptor, ionotropic, AMPA1 (alpha 1); Gria2, glutamate receptor, ionotropic, AMPA2 (alpha 2); Gria3, glutamate receptor, ionotropic, AMPA3 (alpha 3); Grin2a, glutamate receptor, ionotropic, NMDA2A (epsilon 1); Grin2d, glutamate receptor, ionotropic, NMDA2D (epsilon 4); Hprt, hypoxanthine guanine phosphoribosyl transferase; Kitl, kit ligand; Notch1, notch 1; Ntrk2, neurotrophic tyrosine kinase, receptor, type 2; Pcna, proliferating cell nuclear antigen; Ptgs2, prostaglandin-endoperoxide synthase 2; Slc17a6, solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6; Slc17a7, solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7.
Data are expressed as the mean ± SD.
p < .05,
p < .01, compared with the 0-ppm controls by Student’s t-test or Aspin-Welch’s t-test.